Fate Therapeutics Announces Presentations at the 2020 Society for Immunotherapy of Cancer Annual Meeting
October 15 2020 - 8:00AM
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage
biopharmaceutical company dedicated to the development of
programmed cellular immunotherapies for cancer and immune
disorders, today announced that five abstracts for the Company’s
induced pluripotent stem cell (iPSC) product platform were accepted
for presentation at the Society for Immunotherapy of Cancer (SITC)
annual meeting being held virtually from November 9-14, 2020.
Accepted abstracts include clinical data from 15 patients in the
dose-escalation stage of the Company’s Phase 1 clinical trial of
FT500 in advanced solid tumors (NCT03841110), which includes nine
patients in Regimen A (three once-weekly doses of FT500 for up to
two 30-day cycles as monotherapy) and six patients in Regimen B
(three once-weekly doses of FT500 for up to two 30-day cycles in
combination with checkpoint inhibitor therapy). The Company is
currently enrolling the dose-expansion stage of the Phase 1
clinical trial for patients with non-small cell lung cancer or
classical Hodgkin lymphoma who are refractory to, or have relapsed
on, checkpoint inhibitor therapy. Each patient in the
dose-expansion stage is to receive three once-weekly doses of FT500
at 300 million cells per dose, each with IL-2 cytokine support, for
up to two 30-day cycles in combination with the same checkpoint
inhibitor on which the patient failed or relapsed.
Oral Presentation
- Targeting pan-tumor associated antigen
B7H3 via combination of tri-specific killer engager and
off-the-shelf NK cell therapy enhances specificity and function
against a broad range of solid tumors (#470)
Poster Presentations
- Preclinical development of a novel
iPSC-derived CAR-MICA/B NK cell immunotherapy to overcome solid
tumor escape from NKG2D-mediated mechanisms of recognition and
killing (#114)
- Multi-antigen targeting of heterogenous
solid tumors using CAR T cells secreting bi-specific T-cell
engagers (#116)
- iPSC-derived NK cells mediate robust
anti-tumor activity against glioblastoma (#155)
- Preliminary results of an ongoing phase
I trial of FT500, a first-in-class, off-the-shelf, iPSC-derived NK
cell therapy in advanced solid tumors (#380)
All abstracts are scheduled to be available on the SITC website
on November 9, 2020.
About Fate Therapeutics’ iPSC Product
PlatformThe Company’s proprietary induced pluripotent stem
cell (iPSC) product platform enables mass production of
off-the-shelf, engineered, homogeneous cell products that can be
administered with multiple doses to deliver more effective
pharmacologic activity, including in combination with other cancer
treatments. Human iPSCs possess the unique dual properties of
unlimited self-renewal and differentiation potential into all cell
types of the body. The Company’s first-of-kind approach involves
engineering human iPSCs in a one-time genetic modification event
and selecting a single engineered iPSC for maintenance as a clonal
master iPSC line. Analogous to master cell lines used to
manufacture biopharmaceutical drug products such as monoclonal
antibodies, clonal master iPSC lines are a renewable source for
manufacturing cell therapy products which are well-defined and
uniform in composition, can be mass produced at significant scale
in a cost-effective manner, and can be delivered off-the-shelf for
patient treatment. As a result, the Company’s platform is uniquely
capable of overcoming numerous limitations associated with the
production of cell therapies using patient- or donor-sourced cells,
which is logistically complex and expensive and is subject to
batch-to-batch and cell-to-cell variability that can affect
clinical safety and efficacy. Fate Therapeutics’ iPSC product
platform is supported by an intellectual property portfolio of over
300 issued patents and 150 pending patent applications.
About FT500FT500 is an investigational,
universal, off-the-shelf natural killer (NK) cell cancer
immunotherapy derived from a clonal master induced pluripotent stem
cell (iPSC) line. The product candidate is being investigated in an
open-label, multi-dose Phase 1 clinical trial for the treatment of
advanced solid tumors (NCT03841110). The study is designed to
assess the safety and tolerability of FT500 as a monotherapy and in
combination with one of three FDA-approved immune checkpoint
inhibitor (ICI) therapies – nivolumab, pembrolizumab or
atezolizumab – in patients that have failed prior ICI therapy.
Despite the clinical benefit conferred by approved ICI therapy
against a variety of tumor types, these therapies are not curative
and, in most cases, patients either fail to respond or their
disease progresses on these agents. One common mechanism of
resistance to ICI therapy is associated with loss-of-function
mutations in genes critical for antigen presentation. A potential
strategy to overcome resistance is through the administration of
allogeneic NK cells, which have the inherent capability to
recognize and directly kill tumor cells with these mutations.
About Fate Therapeutics,
Inc.Fate Therapeutics is a clinical-stage
biopharmaceutical company dedicated to the development of
first-in-class cellular immunotherapies for cancer and immune
disorders. The Company has established a leadership position in the
clinical development and manufacture of universal, off-the-shelf
cell products using its proprietary induced pluripotent stem cell
(iPSC) product platform. The Company’s immuno-oncology product
candidates include natural killer (NK) cell and T-cell cancer
immunotherapies, which are designed to synergize with
well-established cancer therapies, including immune checkpoint
inhibitors and monoclonal antibodies, and to target
tumor-associated antigens with chimeric antigen receptors (CARs).
The Company’s immuno-regulatory product candidates include
ProTmune™, a pharmacologically modulated, donor cell graft that is
currently being evaluated in a Phase 2 clinical trial for the
prevention of graft-versus-host disease, and a myeloid-derived
suppressor cell immunotherapy for promoting immune tolerance in
patients with immune disorders. Fate Therapeutics is headquartered
in San Diego, CA. For more information, please visit
www.fatetherapeutics.com.
Forward-Looking StatementsThis release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 including statements
regarding the advancement of, plans related to, and the therapeutic
potential of the Company's product candidates, the Company’s
clinical development strategy and plans for the clinical
investigation of its product candidates, and the Company’s
preclinical research and development programs. These and any other
forward-looking statements in this release are based on
management's current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to, the risk of
difficulties or delay in the initiation of any planned clinical
studies, or in the enrollment or evaluation of subjects in any
future clinical studies, the risk that the Company may cease or
delay preclinical or clinical development of any of its product
candidates for a variety of reasons (including requirements that
may be imposed by regulatory authorities on the initiation or
conduct of clinical trials or to support regulatory approval,
difficulties in manufacturing or supplying the Company’s product
candidates for clinical testing, and any adverse events or other
negative results that may be observed during preclinical or
clinical development), the risk that results observed in
preclinical studies of the Company’s product candidates may not be
replicated in ongoing or future clinical trials or studies, and the
risk that the Company’s product candidates may not produce
therapeutic benefits or may cause other unanticipated adverse
effects. For a discussion of other risks and uncertainties, and
other important factors, any of which could cause the Company’s
actual results to differ from those contained in the
forward-looking statements, see the risks and uncertainties
detailed in the Company’s periodic filings with the Securities and
Exchange Commission, including but not limited to the Company’s
most recently filed periodic report, and from time to time in the
Company’s press releases and other investor
communications. Fate Therapeutics is providing the information
in this release as of this date and does not undertake any
obligation to update any forward-looking statements contained in
this release as a result of new information, future events or
otherwise.
Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina@sternir.com
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From Apr 2023 to Apr 2024